RLAY – relay therapeutics, inc. (US:NASDAQ)

News

Relay Therapeutics (RLAY) had its price target raised by HC Wainwright from $14.00 to $19.00. They now have a "buy" rating on the stock.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. [Yahoo! Finance]
Relay Therapeutics (RLAY) had its price target raised by Citizens Jmp from $15.00 to $17.00. They now have a "market outperform" rating on the stock.
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $15.00 to $17.00. They now have an "overweight" rating on the stock.
Relay Therapeutics (RLAY) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com